Back to top

Image: Bigstock

Adma Biologics (ADMA) Stock Sinks As Market Gains: What You Should Know

Read MoreHide Full Article

Adma Biologics (ADMA - Free Report) closed at $3.78 in the latest trading session, marking a -0.26% move from the prior day. This move lagged the S&P 500's daily gain of 0.84%. Elsewhere, the Dow gained 0.96%, while the tech-heavy Nasdaq added 0.81%.

Heading into today, shares of the infectious disease drug developer had lost 14.64% over the past month, lagging the Medical sector's loss of 1.32% and the S&P 500's gain of 0.19% in that time.

Adma Biologics will be looking to display strength as it nears its next earnings release. On that day, Adma Biologics is projected to report earnings of -$0.01 per share, which would represent year-over-year growth of 87.5%. Our most recent consensus estimate is calling for quarterly revenue of $62.55 million, up 52.23% from the year-ago period.

For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.06 per share and revenue of $244.07 million, which would represent changes of +81.82% and +58.41%, respectively, from the prior year.

It is also important to note the recent changes to analyst estimates for Adma Biologics. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Adma Biologics is currently a Zacks Rank #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 101, putting it in the top 41% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on

See More Zacks Research for These Tickers

Normally $25 each - click below to receive one report FREE:

ADMA Biologics Inc (ADMA) - free report >>

Published in